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109Orally administered dipeptidyl peptidase-4 inhibitor
(alogliptin) prevents abdominal aortic aneurysm
formation through an antioxidant effect in rats
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Tomoya Yamashita, MD, PhD,b Kenichi Hirata, MD, PhD,b Yutaka Okita, MD, PhD,a and
Kenji Okada, MD, PhD,a Kobe, Japan
Objective: Dipeptidyl peptidase-4 (DPP-4) inhibitor, a novel antidiabetic drug, has a cardioprotective effect on ischemia-
reperfusion injury through an antioxidant effect. However, the effect of DPP-4 inhibitor on aneurysm formation has not
been investigated. We aimed to test the hypothesis that the DPP-4 inhibitor, alogliptin, attenuates vascular oxidative
stress and thus inhibits abdominal aortic aneurysm (AAA) formation.
Methods: AAAs were created with intraluminal elastase and extraluminal calcium chloride in 36male rats. Rats were divided
into three groups: a lowdose of alogliptin group (groupLD; 1mg/kg/d), a high-dose group (groupHD; 3mg/kg/d), and
a control group (groupC, water). Alogliptin was administered by gastric gavage once daily beginning 3 days before surgery.
On day 7 after aneurysm preparation, reactive oxygen species (ROS) expression was semiquantiﬁed by dihydroethidium
staining, and the oxidation product of DNA produced by ROS, 8-hydroxydeoxyguanosine (8-OHdG), was measured by
immunohistochemical staining. Blood glucose concentrations were measured. Hematoxylin and eosin and elastica Van
Gieson stainings were performed on day 28, and the AAA dilatation ratio was calculated.
Results: On day 7 (six in each group), dihydroethidium staining of the aneurysm wall showed a reduced level of ROS
expression (4.6 6 0.6 in group C, 2.7 6 0.3 in group LD, and 1.7 6 0.5 in group HD; P < .0001) and showed fewer
8-OHdG-positive cells in alogliptin-treated samples (138.167.4 cells in groupC, 102.564.5 cells in groupLD, and66.16
4.5 cells in group HD; P < .0001) The treatment signiﬁcantly reduced messenger RNA expression of matrix metal-
loproteinases (MMPs) in aneurysm walls (relative expression: MMP-2: 2.1 6 0.4 in group C, 1.3 6 0.3 in group LD, and
0.9 6 0.2 in group HD; P < .001; MMP-9: 2.0 6 0.5 in group C, 0.3 6 0.3 in group LD, and 0.3 6 0.2 in group HD;
P < .001). On day 28 (six in each group), the aortic wall in groups LD and HD was less dilated (dilatation ratio: 199.2%6
11.8% in group C, 159.6%6 2.8% in group LD, and 147.1%6 1.9% in group HD; P < .02 group C vs HD) and had higher
elastin content than in group C. The difference in blood glucose levels among the three groups was not signiﬁcant.
Conclusions: The DPP-4 inhibitor, alogliptin, attenuates aneurysm formation and expansion dose-dependently in a rat
AAA model via an antioxidative action. (J Vasc Surg 2014;59:1098-108.)
Clinical Relevance: Abdominal aortic aneurysm (AAA) is a potentially life-threatening condition of rupture, resulted in
high mortality. Mechanisms of AAA formation have been under investigation and remain unclear. Because an effective
pharmaceutical treatment for AAA has not been established, most patients are monitored by annual serial radiologic
evaluation, without any treatment. Alogliptin is an antidiabetic drug that suppresses AAA formation without affecting
normal glucose tolerance. Orally administered alogliptin has some clinical advantages in safety and convenience. Alog-
liptin could be an effective medical therapy for patients with a small AAA or patients in poor general condition who have
been refused a surgical procedure.Abdominal aortic aneurysm (AAA) is a potentially fatal
condition because of the risk of rupture. Ruptured AAA is
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8incidence of AAA has increased during the past 2 decades.3
There is currently no effective prophylaxis for AAA except
invasive surgical or endovascular therapies.
Reactive oxygen species (ROS) have been shown to
play a role in many chronic diseases,4-6 including cardiovas-
cular diseases such as atherosclerosis.7,8 and hyperten-
sion.9,10 Enhanced production of ROS is associated with
localized inﬂammatory responses and can cause progressive
cell and tissue damage, which in the aorta eventually leads
to AAA.11 Although pharmacologic treatment for AAA has
not been established clinically, experimental studies have
demonstrated that genetic and pharmacologic inhibition
of ROS production can inhibit aneurysm formation.12,13
We recently reported that the free radical scavenger edara-
vone prevented aneurysm formation by ROS inhibition in
the rat AAA model, which has proved that oxidative stress
plays a crucial role in pathogenesis of AAA formation.14
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a novel antidiabetic drug, has been shown to exert its car-
dioprotective effect during ischemia-reperfusion injury by
the reduction of ROS production.15 However, the effect
of DPP-4 inhibitor on aneurysm formation has never
been investigated. In the present study, we tested the
hypothesis that the DPP-4 inhibitor, alogliptin, prevents
aneurysm formation through ROS inhibition in an experi-
mental rat AAA model.
METHODS
Rats. The handling and use of laboratory animals in
the experiments in this study conformed to the Guidelines
for Animal Experimentation at Kobe University Graduate
School of Medicine (Permission No. 100608) and the
Guide for the Care and Use of Laboratory Animals
(www.nap.edu/catalog/5140.html). The study used 36
male Sprague-Dawley rats (8 weeks of age, SLC Inc,
Shizuoka, Japan).
AAA preparation. The experimental AAA model was
created by means of simple application of intraluminal elas-
tase and extraluminal calcium chloride, according to our
recent report.16 Brieﬂy, rats anesthetized by intraperito-
neal administration of pentobarbital (1 mg/kg) were
placed under an operating microscope Leica M651 (Leica
Microsystems, Heerburgg, Switzerland) at original
magniﬁcation 6 to 10. After a midline abdominal
incision and exposure of the abdominal aorta, 30 U elastase
(135 U/mg; Elastin Products, Owensville, Mo) was
applied to a 1-cm length of the infrarenal aorta intra-
luminally plus 0.5M CaCl2 (Sigma-Aldrich, Tokyo, Japan)
extraluminally for 20 minutes. Intraluminal saline infusion
alone was performed to elucidate the barotrauma against
the abdominal aortic wall as a preliminary experiment,
which is discussed in the limitations. The abdominal inci-
sion was closed in layers, and the rats were allowed to
recover.
CD26/DPP-4 in aneurysm wall. CD26, also known
as DPP-4, is a multifunctional type II transmembrane
glycoprotein17 expressed in a variety of cells, including
T cells, B cells, macrophages, inﬂammatory mononuclear
cells, and vascular endothelial cells18-21 and involved in
T-cell activation.22 Inhibition of DPP-4 signaling exerts
antiatherosclerotic effects and reduces inﬂammation via
inhibition of monocyte activation and chemotaxis.23 On
day 7, we assessed the expression of CD26-positive cells in
the AAA wall by immunohistochemistry and evaluated
messenger (m)RNA expression of CD26 by quantitative
real-time polymerase chain reaction (RT-PCR) analysis.
Alogliptin administration. Alogliptin was provided
by Takeda Pharmaceutical Company Ltd (Osaka, Japan).
Two different doses (1 and 3 mg/kg/d) were tested for
their effect on the prevention of AAA. Both doses were
previously reported to be sufﬁcient for inhibition of
DPP-4 activity without decreasing the blood glucose
level in normal glucose tolerance.24 The 36 rats were
randomly divided into three groups of 12 rats each: group
LD received low-dose alogliptin (1 mg/kg/d), group HDreceived high-dose alogliptin (3 mg/kg/d), and group C
received water as the control treatment. Alogliptin or water
was given by gastric gavage once daily, starting 3 days
before induction of the AAA.
Blood glucose levels. All rats were fasted overnight,
and the blood glucose levels were measured with the Glu-
test E II system (Sanwa Chemical Lab, Nagoya, Aichi,
Japan).
Macroscopic assessments. On day 28, animals were
anesthetized, and the abdominal aorta was exposed. The
aneurysm diameter, deﬁned as the maximal dimension,
and the aortic diameter at the infrarenal proximal neck
site, were measured under physiologic conditions with an
optical micrometer before harvest. The dilatation ratio
(%) was calculated according to the following formula:
Dilation ratio (%) ¼ (maximal aneurysm diameter/normal
aortic diameter)  100. The harvested aortic aneurysm
was divided into three portions. The ﬁrst portion was
used for pathologic examination, the second for in situ
imaging of superoxide, and the third for quantitative RT-
PCR analysis.
Histologic analysis. Parafﬁn-embedded 5-mm-thick
sections were stained with hematoxylin and eosin (H&E)
for general histologic analysis on day 7 and 28 and with
elastica Van Gieson (EVG) for elastin on day 28. Images
of the sections were captured with a Biozero microscopic
system (BZ 8100, KEYENCE Co, Osaka, Japan) and
assessed using Dynamic cell count BZ-HIC software
(KEYENCE). Areas of elastin in a cross-sectional aortic
wall were measured using Dynamic cell count BZ-HIC
software. Elastin content was calculated by dividing the
elastin-positive area by the cross-sectional media area of the
aortic wall, which was measured using the EVG-stained
sections to highlight internal elastic lamina and external
elastic lamina, and expressed as a percentage. Microscopic
digital images of ﬁve random ﬁelds on each section were
scanned in a frame composed of a 500-  380-mm
rectangle.
Immunohistochemistry. Immunohistochemical stain-
ing was performed on parafﬁn-embedded sections
on day 7 with monoclonal antibody speciﬁc for
8-hydroxydeoxyguanosine (8-OHdG; Japan Institute for
the Control of Aging, Shizuoka, Japan), for CD26 (BD
Biosciences, Erembodegem, Belgium, #559639) and for
CD68 for macrophage (Abcam, Cambridge, Mass;
#ab125212). Brieﬂy, deparafﬁnized sections were incu-
bated overnight at 4C with primary antibody against
8-OHdG (5.0 mg/mL), CD26 (0.5 mg/mL), or CD68
(1 mg/mL). After three washes, sections were incubated
for 30 minutes with secondary antibody antimouse
immunoglobulin G (K4001; Dako, Japan) for 8-OHdG
and CD26 and with secondary antibody antirabbit
immunoglobulin G (K4003; Dako, Japan) for CD68 at
room temperature. Microscopic digital images of ﬁve
random ﬁelds on each section were scanned in a frame
composed of a 500-  380-mm rectangle, and the number
of 8-OHdG-positive cells in aneurysm wall was counted
using Dynamic cell count BZ-HIC software.
Fig 1. A, Immunohistochemical staining of aortic walls at day 7. Sections were stained with CD26 antibody (upper
panels) and CD68 antibody (lower panels) in the control group (group C), and the low-dose (LD) and high-dose (HD)
groups. The arrowheads indicate positive cells (scale bar ¼ 100 mm). B,Messenger RNA expression of CD26 at day 7 in
the normal native aorta (normal) and aneurysm wall in the control group that received water (group C). Statistical
analysis was done using the Student t-test. *P < .001 vs normal. The range bar shows the standard deviation.
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aneurysm was embedded in Tissue-Tek O.C.T.
Compound (Sakura Finetek, Zoeterwoude, Netherland),
immediately frozen, and cut into 10-mm sections. Dihy-
droethidium (DHE; Invitrogen, Tokyo, Japan) was used to
evaluate tissue superoxide levels in situ, as previously
described.25 Day 7 and 28 sections were incubated with
DHE in phosphate-buffered saline in a dark, humidiﬁed
chamber for 30 minutes at 37C. DHE ﬂuorescence was
detected through a 580-nm ﬁlter, and DHE ﬂuorescence
images were scanned with a Biozero microscope in a frame
composed of 500-  380-mm rectangles. DHE ﬂuores-
cence of arterial sections was quantiﬁed using Dynamic cell
count BZ-HIC software. The mean ﬂuorescence was
semiquantiﬁed and expressed relative to values obtained for
normal rat.
Quantitative RT-PCR analysis. Total RNA was iso-
lated from the aneurysm samples using an RNeasy ﬁbrous
tissue mini-kit (Qiagen, Valencia, Calif) according to the
manufacturer’s instruction. The RNA was reverse-
transcribed to complimentary DNA and ampliﬁed using
a high-capacity complimentary DNA reverse-transcription
real-time kit (Applied Biosystems, Foster City, Calif).Tissue from the day 7 aneurysm wall underwent
PCR analysis for quantitation of mRNA expression of
MMP-2, MMP-9, and CD26 using the ABI Prism
7500 sequence detector system (Applied Biosystems)
with TaqMan universal PCR master mix and TaqMan real-
time PCR primers (Applied Biosystems). The expression
level of each mRNA was divided by mRNA expression level
of the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase.
Gelatin zymography. Proteins from aortic specimens
on day 7 were extracted using a buffer containing 50mM
Tris-HCl (pH 7.5), 150mM NaCl, 1% Triton X-100,
0.2% sodium dodecyl sulfate, and 1 mM ethylenedi-
aminetetraacetic acid, supplemented with protease inhibi-
tors (20 mg/mL aprotinin, 10 mg/mL leupeptin, and
1 mM phenylmethylsulfonyl ﬂuoride). To determine
gelatinolytic activities of MMP-2 and MMP-9 in the aorta,
a gelatin-zymography kit (Primary Cell Co, Hokkaido,
Japan) was used according to the manufacturer’s instruc-
tions. The protein concentration was standardized with
a microbicinchoninic acid protein assay kit (Pierce, Rock-
ford, Ill). Aliquots of protein (20 mg) underwent sodium
dodecyl sulfate gel electrophoresis, and densitometric
Fig 2. A, Aneurysm formation of abdominal aorta at 28 days in each group. Rats in the control group (group C)
received water, rats in the low-dose group (group LD) received 1 mg/kg/d alogliptin, and rats in the high-dose group
(group HD) received 3 mg/kg/d alogliptin. B,Dilatation ratio in each group. *P < .02 group C vs HD. The range bar
shows the standard deviation.
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ware (National Institutes of Health, Bethesda, Md).
Statistical analysis. Continuous variables are ex-
pressed as mean 6 standard deviation. Comparisons
among multiple groups were performed using one-way
analysis of variance, whereas comparisons between two
groups were made using the Student t-test. All P values
were two-sided and considered statistically signiﬁcant at
P < .05. If the one-way analysis of variance was signiﬁcant,
a post hoc analysis with the post hoc Games-Howell test
was used to determine the signiﬁcance among the groups.Data were analyzed with SPSS 17 software (SPSS Inc,
Chicago, Ill).
RESULTS
The surgical procedure in each group required w30
minutes to complete. Success rate was 100%. No technical
failures or deaths occurred during the surgical procedures,
and all animals survived to the end points. Six rats in each
group were used for biochemical examinations of ROS
expression, immunohistochemistry, RT-PCR analysis, and
gelatin zymography on day 7. Another six rats in each
Fig 3. Histologic ﬁndings of abdominal aortic aneurysm at day 28. Sections were stained with (A) hematoxylin and
eosin and (B) elastica von Gieson stain in each group (upper panels: original magniﬁcation, 40; scale bar ¼ 300 mm;
lower panels: original magniﬁcation, 400; scale bar ¼ 100 mm). C, Quantitative analysis of elastin content is shown.
Data are expressed as mean 6 standard deviation (range bars) for six rats per group. Group C, Rats received water;
group HD, rats received high-dose alogliptin (3 mg/kg/d); group LD, rats received low-dose alogliptin (1 mg/kg/d);
normal, normal native aorta, Statistical analysis was by one-way analysis of variance with post hoc Games-Howell test.
*P < .0001 vs all other groups.
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ratio and histologic examination (H&E, EVG staining)
on day 28.
CD26/DPP-4 expression in aneurysm wall. The
CD26 protein on the mononuclear cells was stained in
AAA walls (Fig 1, A, upper panel) and mRNA expression
of CD26 was signiﬁcantly higher in AAA walls than in theaortas of control animals (Fig 1, B). Immunohistochemical
staining of CD68 conﬁrmed that CD26 protein was
expressed on macrophages (Fig 1, A, lower panel).
Blood glucose levels. Blood glucose levels did not
differ signiﬁcantly among the groups and was 105.3 6
3.6 mg/dL in group C, 105.5 6 15.0 mg/dL in group
LD, and 102.3 6 6.1 mg/dL in group HD.
Fig 4. A, Reactive oxygen species expression stained with dihydroethidium in aneurysm walls at day 7 is shown in the
lower panels (original magniﬁcation, 400), whereas the upper panels show correspondent hematoxylin and eosin
staining in each group. B, Reactive oxygen species expression in aneurysm walls at day 28 is shown (original
magniﬁcation, 400; scale bar ¼ 100 mm). C, The mean ﬂuorescence in a high-power ﬁeld. All data are expressed as
mean 6 standard deviation (range bars) for six rats per group. Statistical analysis was by one-way analysis of variance
with post hoc Games-Howell test. *P < .01 vs all other groups on day 7, *P < .01 group C vs HD on day 28. Group C,
rats received water; group HD, rats received high-dose alogliptin (3 mg/kg/d); group LD, rats received low-dose
alogliptin (1 mg/kg/d); normal, normal native aorta.
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day 28 are shown in Fig 2, A. Aortic dilatation and dila-
tation ratio in DPP-4-treated groups (groups LD and HD)
were signiﬁcantly lower than that in the water-treated
group C (dilatation ratio: 199.2% 6 11.8% in group C,
159.6% 6 2.8% in group LD, and 147.1% 6 1.9% in group
HD; P < .02 group C vs HD; Fig 2, B).Microscopic assessments. Microscopic ﬁndings on
day 28 are shown in Fig 3, A and B. The aortic wall in
group C was the thinnest, with loose adventitia, whereas
aortic walls in groups LD and HD were more thickened,
accompanied with intimal hyperplasia and robust adven-
titia. Elastin was regenerated in the media in groups LD
and HD. Elastin content in the aortic wall increased
Fig 5. A, Immunostaining of 8-hydroxydeoxyguanosine (8-OHdG)-positive cells in aneurysm walls at day 7 is shown
(original magniﬁcation, 400; scale bar ¼ 100 mm). B, The number of 8-OHdG cells was counted in a high-power
ﬁeld. All data are expressed as mean 6 standard deviation (range bars) for six rats per group. Statistical analysis
was by one-way analysis of variance with post hoc Games-Howell test. *P < .0001 vs all other groups. Group C,
rats received water; group HD, rats received high-dose alogliptin (3 mg/kg/d); group LD, rats received low-dose
alogliptin (1 mg/kg/d); normal, normal native aorta.
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group C (8.0% 6 0.6% in group C, 9.8% 6 0.7% in group
LD, and 11.3% 6 0.4% in group HD; P < .0001 vs all
other groups; Fig 3, C). This increase in elastin was dose-
dependent, being lowest in groups C and correspond-
ingly higher in groups LD, and HD.
Effect of DPP-4 inhibitor on ROS expression and
8-OHdG in AAA walls of rats. To evaluate ROS expres-
sion in the aneurysm wall on days 7 and 28 (Fig 4, A and
B), DHE staining was performed on sections of aorta from
each group. In each group on day 7, the most intense
DHE staining was basically observed on endothelial cells in
the intima and smooth muscle cells in the media, which was
conﬁrmed by correspondent H&E staining in each group
using serial sections. Another staining was observed in the
loose tissue of the adventitia in group C. Similar ﬁndings
were observed in the adventitia in groups LD and HD.
The DHE staining on day 7 showed that ROS expres-
sion in the aneurysm wall was signiﬁcantly lower in the
alogliptin-treated group compared with the control group
(4.6 6 0.6 in group C, 2.7 6 0.3 in group LD, and
1.7 6 0.5 in group HD; P < .01 vs all other groups),
whereas a signiﬁcant difference was observed betweengroup C vs group HD on day 28 (3.4 6 0.3 in group C,
2.9 6 0.3 in the group LD, 2.6 6 0.4 in group HD;
P < .01 group C vs HD; Fig 4, C). The number of
8-OHdG-positive cells in aneurysm walls was signiﬁcantly
lower in alogliptin-treated groups than in the control group
(138.1 6 7.4 cells in group C ,103 6 4.5 cells in group
LD, and 66.1 6 4.5 cells in group HD; P < .01 vs all other
groups; Fig 5, A and B). A signiﬁcant dose-dependent
decrease in ROS expression and 8-OHDG staining
was observed in the aneurysm walls between groups LD
and HD.
Effect of DPP-4 inhibitor on MMPs expression and
activity. mRNA expression of MMP-2 and MMP-9 was
signiﬁcantly lower in alogliptin-treated groups than in the
control group (MMP-2: 2.16 0.4 in group C, 1.36 0.3 in
group LD, 0.9 6 0.2 in group HD; MMP-9: 2.0 6 0.5 in
group C, 0.3 6 0.3 in group LD, 0.3 6 0.2 in group HD;
Fig 6, A). Gelatinolytic activities of MMP-2 and MMP-9
were also signiﬁcantly lower in alogliptin-treated groups
compared with the control group (MMP-2: 124.3 6 5.1 in
group C, 78.5 6 6.6 in group LD, and 68.6 6 16.8 in
group HD; proMMP-2: 126.7 6 10.7 in group C, 85.36
3.4 in group LD, and 66.8 6 17.7 in group LD; MMP-9:
Fig 6. A,Messenger RNA expression of matrix metalloproteinase (MMP)-2 and MMP-9 in the aneurysm wall at day 7,
with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the housekeeping gene. *P < .01 vs group C.
B, Gelatin zymography demonstrates gelatinolytic activity of MMP-2 and MMP-9. C, Densitometric analysis of MMP-
2 (left), Pro-MMP (middle) and MMP-9 (right) activities. All data are expressed as mean 6 standard deviation for six
rats per group. Statistical analysis was by one-way analysis of variance with post hoc Games-Howell test. *P < .01 vs
group C. Group C, rats received water as the control; group HD, rats received high-dose alogliptin (3 mg/kg/d); group
LD, rats received low-dose alogliptin (1 mg/kg/d); normal, normal native aorta.
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81.3 6 10.1 in group HD; Fig 6, B and C).
DISCUSSION
This study showed that the DPP-4 inhibitor, alogliptin,
can prevent AAA formation through an antioxidative
action by a mechanism that is similar to its cardioprotective
effect against ischemia-reperfusion injury by reduction of
ROS production.15 The results of the current study suggest
that alogliptin might be an effective oral pharmacologic
agent for AAA treatment in clinical practice.
ROS have been shown to play a central role in many
chronic disease, including cardiovascular diseases such as
atherosclerosis and hypertension.5,9,26 Increased produc-
tion of ROS is associated with localized inﬂammatory
responses that can cause progressive cell and tissue damage,
which has been reported to be closely linked to the patho-
genesis of AAA.11,27 Excessive production of ROS mediatesactivation of matrix-degrading enzymes and inﬂammation,
resulting in the reduction of medial elastin content and
aortic wall thinning, leading to aneurysm.7,27-30 In this
study, aneurysm formation was also associated with
increased ROS expression and oxidative DNA damage
(8-OHdG-positive cells) in the aortic wall. Expression
of MMP-2 and MMP-9 mRNAs was increased in the
aneurysm walls.
Aneurysm formation can be theoretically inhibited by
antioxidants. We proved that ROS play a crucial role in
aneurysm formation in this rat AAA model.14 Other anti-
oxidants, such as apocynin13 and vitamin E,31 have been
recently reported to prevent AAA formation. DPP-4 inhib-
itor is widely used for patients with type 2 diabetes mellitus.
As mentioned above, DPP-4 inhibitor suppressed expres-
sion of ROS in an animal model of ischemia-reperfusion
injury.15 The present study demonstrated that the DPP-4
inhibitor, alogliptin, has antioxidant properties that can
Fig 7. A, Aneurysm formation in the abdominal aorta at 7 days in the saline group. B and C, Histologic ﬁndings of
abdominal aorta at day 7 in the saline group. Sections were stained with hematoxylin and eosin (H&E; B) and elastica
von Gieson (EVG; C) (original magniﬁcation, 400). D, Reactive oxygen species expression is shown in aortic walls at
day 7 in the saline group (original magniﬁcation, 400).
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formation. Alogliptin suppressed not only ROS dose-
dependently, particularly in the early phase (day 7), but
also recruitment of inﬂammatory CD68/CD26-positive
cells, which prevented the destruction of medial elastin in
the current AAA model. MMP-2 and MMP-9 mRNA
expression was reduced, and the activities of the enzymes
in the aortic wall were effectively decreased through ROS
elimination by alogliptin treatment. Notably, even treat-
ment with a low-dose of alogliptin decreased the mRNA
expression of MMP-9 as effectively as a high-dose treat-
ment. Previous studies have shown that MMP-2 and
MMP-9 are required for AAA formation32,33 and that
ROS play a major role in the activation of MMPs.29 These
ﬁndings strongly suggest that alogliptin ameliorates aortic
wall degeneration by reducing oxidative stress, resulting
in the prevention of aortic dilatation.
A novel ﬁnding in the present study is that orally
administered alogliptin can prevent aneurysm formation.
Oral administration has many clinical advantages and appli-
cability. Effective pharmacotherapy for AAA might be of
signiﬁcant beneﬁt for patients with small AAA or those in
poor general condition who cannot undergo surgical
procedures. Some pharmacologic agents have been re-
ported to prevent AAA formation but have not been
used clinically. We recently reported the efﬁcacy of edara-
vone against AAA.14 However, edaravone is clinically
used by intravenous administration. We believe that orally
administered alogliptin has a high potential as a clinical
therapeutic agent for AAA without affecting normal
glucose tolerance.
Alogliptin has some clinical side effects, such as head-
ache and dizziness, with doses >400 mg,34 but no side
effects were noted with the 3 mg/kg/d in this study
with rats or in a previous report.24 The side effects of
several pharmaceutical agents with inhibitory effect on
AAA formation have been reported.35,36 Statins have side
effects, such as acute kidney failure and liver failure,37
and angiotensin-receptor blockers also have side effects
such as hypotension38 and kidney failure.39 Further studiesto test other doses of this DPP-4 inhibitor are required to
evaluate the balance between its efﬁcacy and safety in the
prevention of AAA formation.
This study has some limitations that deserve attention.
This AAA model is simple and easy to perform and is highly
reliable and reproducible to create a saccular aneurysm.16
When we used normal saline intraluminally instead of elas-
tase, aortic dilatation was 126.3% on day 7 (Fig 7, A),
which did not meet the criteria of aneurysm in the current
study. Indeed, the surgical procedure has a small amount of
barotrauma against the aortic wall. H&E and EVG staining
in the group demonstrated a little thicker aortic wall than
that of normal aorta; however, elastin content stained by
EVG seemed to be preserved on day 7 (Fig 7, B and C).
DHE staining in the group (Fig 7, D) demonstrated
increased expression of ROS compared with normal aorta,
but this was weaker than that in control aorta (group C,
elastase and calcium chloride). However, the stress was
similarly applied to the aortic walls in all groups.
Because this AAA model in rats is created by elastase
and calcium chloride, it does not completely mimic the
human AAA because it lacks several prominent features
of the human lesion such as atherosclerosis and intralumi-
nal thrombosis.
The third limitation is the lack of evaluation of proin-
ﬂammatory cytokines and the analysis of signal transduc-
tion for antioxidative effects by alogliptin. We proved the
potential causal relationship between ROS inhibition and
alogliptin’s vascular protective effect indirectly by dose-
dependent fashion.
CONCLUSIONS
This study demonstrated that the DPP-4 inhibitor,
alogliptin, attenuates aneurysm formation dose-
dependently in rat model of AAA via an antioxidative
action and might be an effective oral pharmacologic agent
for AAA treatment in clinical practice.
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